Yen-Ta Huang Taiwan

Dr. Yen-Ta Huang is currently a Clinical Associate Professor in the Surgical Intensive Care Unit of the Hospital affiliated with the College of Medicine, National Cheng Kung University, and serves as the convener of the Evidence-Based Medicine Teaching Group at National Cheng Kung University Hospital (NCKUH). During his tenure at Hualien Tzu Chi Medical Center, he served as an attending physician in several emergency and critical care units, including the Department of Emergency Medicine, the Medical Intensive Care Unit, the Surgical Intensive Care Unit, and Experimental Surgery. He also held administrative positions such as Acting Director of the Second Medical Intensive Care Unit and of Experimental Surgery. Dr. Huang received his Bachelor of Medicine degree from National Taiwan University in 2000 and completed his residency training at Hualien Tzu Chi Medical Center, successively obtaining board certifications in Internal Medicine (2003), Emergency Medicine (2005), and Critical Care Medicine (2009). He earned his Master's (2006) and Doctoral (2011) degrees from the Institute of Pharmacology and Toxicology at Tzu Chi University, and was subsequently promoted to Assistant Professor (2011) and Associate Professor (2016) in the Department of Pharmacology. Through the prestigious Takeda Medical Scholarship, he served as a visiting scholar at the Department of Emergency and Critical Care Medicine, Nagoya University, Japan, from November 2014 to May 2015, greatly broadening his international research horizons. He is extensively involved in professional medical society affairs. He currently serves as a director of the Taiwan Society of Emergency and Critical Care Medicine, while also serving as deputy convener of its Research Committee and Academic Committee, and as a member of its Editorial and Publication Committee, Review Committee, and Public Affairs and Communication Committee. In addition, he currently serves as deputy convener of the Education Committee and a member of the Academic Committee of the Society of Critical Care Medicine, Republic of China. Dr. Huang also serves as a supervisor of the Taiwan Society of Acute Kidney Disease and as a member of the Inter-Society Trauma and Critical Care Integration Task Force of the Taiwan Trauma Association. Dr. Huang's research spans both basic and clinical medicine. His basic medical research focuses on cancer research and proximal renal tubular toxicity, while his clinical research demonstrates his expertise in the field of evidence-based medicine. Over the past five years, he has published nearly 80 systematic reviews and (network) meta-analyses or evidence-based works in domestic and international peer-reviewed journals, with several studies appearing in internationally renowned, top-tier journals ranked in the top 10% by citation rate. According to the ScholarGPS website rankings, Dr. Huang ranked within the global top 1% in the field of meta-analysis for 2025. Notably, Dr. Huang served as chief advisor for the 2020 Taiwan Acute Kidney Injury Consensus and the 2021 Taiwan Clinical Practice Guidelines for Primary Aldosteronism, reflecting his leadership role in the development of national-level clinical guidelines and his commitment to advancing the practice of evidence-based medicine in Taiwan.

20th September 2026 Sunday

Time	Session

12:40 13:45	Lunch symposium: Polymyxin B Hemoadsorption in Sepsis Shuei-Liong Lin Moderator Yuh-Min Chen Moderator Opening Targeted Polymyxin B Hemadsorption in Sepsis: Lessons from Japanese Experience and Patient Selection Kent Doi Speaker Organ crosstalk in AKITargeted Polymyxin B Hemadsorption in Sepsis: Lessons from Japanese Experience and Patient Selection From Guidelines to Bayesian Trials: How Should We Interpret Polymyxin B Hemoadsorption in Sepsis? Yen-Ta Huang Speaker From Guidelines to Bayesian Trials: How Should We Interpret Polymyxin B Hemoadsorption in Sepsis?Polymyxin B hemoadsorption has occupied an unusually contested place in sepsis care, and the way authoritative bodies describe it has shifted over time. This talk traces that evolution—from the 2020 Taiwan AKI consensus through the 2021 and 2026 Surviving Sepsis Campaign guidelines—and uses the changing recommendations as a lens on the methodological debates that underlie them. From an evidence-based medicine standpoint, the controversy is less about the device than about how we generate and grade evidence. I will first examine the frequentist evidence base, including our network meta-analysis of blood purification therapies for severe infection and sepsis/septic shock published in Critical Care Medicine. I will outline what a network meta-analysis adds—coherent ranking across multiple modalities, indirect comparison, and explicit quantification of heterogeneity—while being candid about its limitations, including reliance on the transitivity assumption, sparse networks, and the fragility of mortality estimates pooled from heterogeneous trials. I will then turn to the recently reported TIGRIS trial, which used a Bayesian, enrichment-based phase 3 design with prespecified borrowing from the EUPHRATES treatable cohort. I will highlight the strengths of the Bayesian presentation—direct posterior probabilities of benefit, transparent incorporation of prior evidence, and efficiency in a rare, mechanistically defined phenotype—alongside the cautions it demands: sensitivity to prior choice, the open-label design, and the gap between a high posterior probability and a confirmed effect. Bringing these strands together, the talk offers a multifaceted, methodology-driven reading of polymyxin B hemoadsorption in sepsis, and a transferable framework for clinicians facing the increasingly common situation in which guidelines, frequentist syntheses, and Bayesian trials appear to diverge. Q&A Room 2

Time

Session

12:40

13:45

Lunch symposium: Polymyxin B Hemoadsorption in Sepsis

Shuei-Liong Lin Moderator

Yuh-Min Chen Moderator

Opening
Targeted Polymyxin B Hemadsorption in Sepsis: Lessons from Japanese Experience and Patient Selection

Kent Doi Speaker Organ crosstalk in AKITargeted Polymyxin B Hemadsorption in Sepsis: Lessons from Japanese Experience and Patient Selection
From Guidelines to Bayesian Trials: How Should We Interpret Polymyxin B Hemoadsorption in Sepsis?

Yen-Ta Huang Speaker From Guidelines to Bayesian Trials: How Should We Interpret Polymyxin B Hemoadsorption in Sepsis?Polymyxin B hemoadsorption has occupied an unusually contested place in sepsis care, and the way authoritative bodies describe it has shifted over time. This talk traces that evolution—from the 2020 Taiwan AKI consensus through the 2021 and 2026 Surviving Sepsis Campaign guidelines—and uses the changing recommendations as a lens on the methodological debates that underlie them. From an evidence-based medicine standpoint, the controversy is less about the device than about how we generate and grade evidence. I will first examine the frequentist evidence base, including our network meta-analysis of blood purification therapies for severe infection and sepsis/septic shock published in Critical Care Medicine. I will outline what a network meta-analysis adds—coherent ranking across multiple modalities, indirect comparison, and explicit quantification of heterogeneity—while being candid about its limitations, including reliance on the transitivity assumption, sparse networks, and the fragility of mortality estimates pooled from heterogeneous trials. I will then turn to the recently reported TIGRIS trial, which used a Bayesian, enrichment-based phase 3 design with prespecified borrowing from the EUPHRATES treatable cohort. I will highlight the strengths of the Bayesian presentation—direct posterior probabilities of benefit, transparent incorporation of prior evidence, and efficiency in a rare, mechanistically defined phenotype—alongside the cautions it demands: sensitivity to prior choice, the open-label design, and the gap between a high posterior probability and a confirmed effect. Bringing these strands together, the talk offers a multifaceted, methodology-driven reading of polymyxin B hemoadsorption in sepsis, and a transferable framework for clinicians facing the increasingly common situation in which guidelines, frequentist syntheses, and Bayesian trials appear to diverge.
Q&A

Room 2